drugset
drugset / Trial / NCT00282230

A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients

NCT00282230 ↗

Phase 2 Terminated 150 enrolled Astellas Pharma Inc Astellas Pharma US, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

A study to evaluate the safety and efficacy of Prograf/FK778 in de novo kidney transplant patients

Timeline

Start
2003-11
Primary completion
—
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject MANITIMUS Small molecule — —

Indications

No indication recorded.